Pzena Investment Management Adds $7M in Fresenius Medical Care AG ($FMS)
Key Points
- Pzena Investment Management changed its Fresenius Medical Care AG ($FMS) stake by 2.03% last quarter, boosting to 15,052,822 shares worth $336.73 million.
- Wall Street's consensus rating on $FMS is Hold and an average price target of $25.79.
- $FMS last traded around $22.37.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Pzena Investment Management increased its position in Fresenius Medical Care AG ($FMS) by 2.03% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,052,822 shares of Fresenius Medical Care AG after buying 299,986 shares during the quarter. Pzena Investment Management's holdings in Fresenius Medical Care AG were worth $336.73 million as of its most recent filing.
Fresenius Medical Care AG Stock Down 3.2%
Shares of Fresenius Medical Care AG ($FMS) traded around $22.37 on Saturday, down 3.2% for the day.
Fresenius Medical Care AG Earnings
Fresenius Medical Care AG Dividend
Analysts Set New Price Targets
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Get Fresenius Medical Care AG alerts
New 13F filings, insider trades, and analyst moves on $FMS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.